RANI Stock Forecast: Rani Therapeutics Holdings, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Rani Therapeutics Holdings, Inc. is $6. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 63 of 100 as at 18 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Rani Therapeutics Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (89): Sales and profits are climbing, and climbing faster than before.
Quality (19): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
RANI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on RANI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Oct 2026 | Chardan Capital | Maintains | Buy | $6.00 |
| 21 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $11 |
| 18 Aug 2026 | Chardan Capital | Initiates | Buy | $6.00 |
| 20 May 2026 | Canaccord Genuity | Maintains | Buy | $5.00 |
| 1 Apr 2026 | Canaccord Genuity | Maintains | Buy | — |
| 27 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Oct 2025 | HC Wainwright & Co. | Assumes | Buy | $11 |
| 20 Oct 2025 | Maxim Group | Maintains | Buy | — |
| 16 May 2025 | Oppenheimer | Maintains | Outperform | — |
| 3 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Feb 2025 | Canaccord Genuity | Maintains | Buy | — |
| 7 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Aug 2024 | Oppenheimer | Initiates | Outperform | — |
| 25 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 June 2024 | Maxim Group | Initiates | Buy | — |
| 13 June 2024 | Rodman & Renshaw | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RANI.
This page is one stock. Monday covers all of them.
RANI appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
RANI vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 19 Nov 2026, Rani Therapeutics Holdings, Inc. returned −66.8% against +9.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
RANI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 10.8×
- Price / book
- 2.1×
- EV / EBITDA
- —
Cheaper than 12% of US stocks
Cheaper than 43% of US stocks
- Revenue growth (YoY)
- 0.0%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
Higher than 29% of US stocks
- Return on equity
- −233.6%
- Return on assets
- −69.7%
- Dividend yield
- —
Higher than 6% of US stocks
Higher than 5% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Rani Therapeutics Holdings, Inc. has a market value of $74.8M and an enterprise value of $40.1M.
Revenue in the twelve months to 30 June 2026: $4.9M.
Net income over the same four quarters: −$33.4M, a −685.3% net margin.
Diluted earnings per share, trailing twelve months: −$0.27.
Free cash flow in the twelve months to 30 June 2026: −$20.3M.
Rani Therapeutics Holdings, Inc. employs 69 people — $71K of revenue per employee.
Data provided by Twelve Data
RANI and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at RANI’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Rani Therapeutics Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about RANI
What is the RANI stock price forecast for 2026-2027?
The median 12-month analyst price target for Rani Therapeutics Holdings, Inc. is $6, with estimates ranging from $5 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is RANI stock a buy right now?
Of the 5 analysts covering Rani Therapeutics Holdings, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rani Therapeutics Holdings, Inc. 63 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank RANI?
As at 18 Nov 2026, Rani Therapeutics Holdings, Inc. ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (89 of 100).
Will RANI stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts is $6, and Ticker Nerd's factor model ranks Rani Therapeutics Holdings, Inc. 63 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the RANI stock forecast for 2030?
No analyst covering Rani Therapeutics Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RANI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $11 over the next 12 months.
How has RANI stock performed over the past year?
Rani Therapeutics Holdings, Inc. returned -66.8% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Rani Therapeutics Holdings, Inc. do?
Rani Therapeutics Holdings, Inc. Class A Common Stock represents equity in Rani Therapeutics, a clinical-stage biotherapeutics company focused on oral delivery technologies for biologics and other drugs. The company’s core product is the RaniPill capsule, a proprietary platform designed to administer large-molecule therapies through the gastrointestinal tract, offering an alternative to injections and infusions.
About Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. Class A Common Stock represents equity in Rani Therapeutics, a clinical-stage biotherapeutics company focused on oral delivery technologies for biologics and other drugs. The company’s core product is the RaniPill capsule, a proprietary platform designed to administer large-molecule therapies through the gastrointestinal tract, offering an alternative to injections and infusions. Rani Therapeutics develops this technology for use across multiple therapeutic areas, including peptides, proteins, antibodies, and oligonucleotides. Its business is centered on advancing drug-delivery solutions that may support patients, physicians, and healthcare systems by making biologic administration more convenient. The company operates in the biotechnology and health care life sciences sectors, where oral delivery platforms are an important area of innovation.
CEO Mr. Talat Imran · 69 employees · United States · https://www.ranitherapeutics.com